Beijing, Sept 2, 2026 — China’s Center for Medical Device Evaluation (CMDE) released six draft registration and review guidelines covering gamma beam stereotactic radiotherapy systems, implantable cardiac pacemakers, and hemodynamic monitoring products, opening a public comment period through Oct 8, 2026, as regulators tighten technical standards for high-risk medical equipment.

Policy Snapshot

Attribute	Detail
Issuer	Center for Medical Device Evaluation (CMDE), National Medical Products Administration
Document	Six Registration and Review Guidelines for Medical Devices (Draft for Comments)
Total guidelines	6
Comment deadline	Oct 8, 2026
Lead guideline	Gamma Beam Stereotactic Radiotherapy System Registration and Review Guiding Principles

Guidelines and Contacts

No.	Guideline	Contact	Email	Phone
1	Gamma Beam Stereotactic Radiotherapy System	He Liping	help@cmde.org.cn	010-86452614
1	Medical Electron Linear Accelerator	He Liping	help@cmde.org.cn	010-86452614
2	Electronic Infusion Pump	Zhong Youjin	zhongyj@cmde.org.cn	010-86452610
2	Implantable Cardiac Pacemaker (2026 Revision)	Zhong Youjin	zhongyj@cmde.org.cn	010-86452610
3	Implantable Pacemaker Lead (2026 Revision)	Wang Ying	wangying@cmde.org.cn	010-86452612
4	Hemodynamic Monitoring Products	Zhang Song	zhangsong@cmde.org.cn	010-86452608

Market Impact Analysis

The six draft guidelines span high-value therapeutic and monitoring modalities, signaling CMDE’s intent to standardize market entry for devices with significant clinical and capital investment implications. The inclusion of gamma beam stereotactic radiotherapy systems and medical electron linear accelerators reflects growing regulatory attention to precision radiation oncology as China expands cancer treatment infrastructure. By establishing clear registration benchmarks for these advanced systems, regulators are reducing uncertainty for domestic and international radiotherapy equipment makers navigating a market with rising demand but historically uneven technical review standards.

The 2026 revisions for implantable cardiac pacemakers and pacemaker leads suggest updated safety and performance requirements, potentially incorporating lessons from recent post-market surveillance data and international standards evolution. For cardiovascular device manufacturers, the revised guidelines may introduce new electrical safety, biocompatibility, or longevity testing protocols that could require design modifications or additional validation studies for pending applications.

The electronic infusion pump and hemodynamic monitoring product guidelines address categories with high hospital penetration and direct patient safety impact. Standardized registration requirements for these devices are likely to accelerate review timelines while elevating the compliance floor for mid-tier domestic manufacturers that have historically relied on fragmented local approvals.

Forward-Looking Statement

Industry analysts expect the finalized six guidelines to take effect in early 2027, establishing the technical baseline for device registrations across radiation oncology, cardiac rhythm management, and critical care monitoring through the remainder of the decade. The Oct 8 comment deadline leaves a five-week window for industry input, suggesting regulators aim to move quickly to close regulatory gaps in these high-priority categories. Companies with pending applications or pipeline products in the covered areas should review the drafts immediately, as the 2026 revisions for pacemakers and leads may introduce requirements not anticipated under previous guidance. The bulk release approach reinforces CMDE’s shift toward systematic, catalog-wide standardization rather than reactive, product-specific rulemaking.-China Health Reform Pulse

Policy Source: https://www.cmde.org.cn/xwdt/zxyw/20260904134545142.html

Beijing, Sept 1, 2026 — China’s Center for Medical Device Evaluation (CMDE) released 16 draft registration and review guidelines for Class II in vitro diagnostic (IVD) reagents and medical devices, opening a public comment period through Oct 8, 2026, as regulators standardize market entry requirements for diagnostic testing products including parathyroid hormone assay reagents.

Regulatory Snapshot

Attribute	Detail
Issuer	Center for Medical Device Evaluation (CMDE), National Medical Products Administration
Document	16 Guiding Principles for Registration and Review of Class II In Vitro Diagnostic Reagents and Medical Devices (Draft for Comments)
Lead guideline	Parathyroid Hormone Assay Reagent Registration and Review Guiding Principles
Total guidelines	16
Product class	Class II in vitro diagnostic reagents and medical devices
Comment deadline	Oct 8, 2026
Submission	Contact details per attached list

Key Scope

The batch covers registration and review technical standards for 16 categories of Class II IVD reagents and devices. The lead document addresses parathyroid hormone assay reagents, with the full portfolio spanning diverse diagnostic testing categories.

Market Impact Analysis

The simultaneous release of 16 draft guidelines represents a significant standardization effort for mid-risk diagnostic products, creating a comprehensive regulatory roadmap for IVD manufacturers navigating China’s Class II registration pathway. For domestic and international diagnostic makers, the consolidated guidance reduces interpretive ambiguity during application preparation, potentially shortening registration timelines by clarifying technical documentation, performance evaluation, and clinical evidence requirements.

The Oct 8 comment deadline provides a five-week window for industry feedback, suggesting regulators aim to finalize the guidelines by year-end. The focus on Class II IVD reagents—a category that includes immunoassay kits, clinical chemistry reagents, and molecular diagnostic products—signals intensified scrutiny of diagnostic devices that are widely used in clinical laboratories but produced by a fragmented supplier base.

Forward-Looking Statement

Industry analysts expect the finalized 16 guidelines to take effect in early 2027, establishing the definitive regulatory baseline for Class II IVD registrations through the remainder of the decade. Manufacturers with pending applications or pipeline products in the covered categories should review the drafts closely, as final versions may introduce new analytical performance requirements or clinical validation standards not explicitly mandated under previous informal guidance. The bulk release approach suggests CMDE is moving toward systematic catalog-wide standardization rather than reactive, product-specific rulemaking, a shift that could accelerate overall review efficiency but demands proactive compliance monitoring across broad diagnostic portfolios.-China Health Reform Pulse

Policy Source: https://www.cmde.org.cn/flfg/zdyz/zqyjg/20260901133826130.html

Beijing, Sept 1, 2026 — China’s Center for Medical Device Evaluation (CMDE) released 59 draft registration and review guidelines for Class II active medical devices, opening a public comment period through Oct 8, 2026, as regulators standardize market entry requirements for powered equipment ranging from negative pressure suction devices to electronic diagnostic instruments.

Regulatory Snapshot

Attribute	Detail
Issuer	Center for Medical Device Evaluation (CMDE), National Medical Products Administration
Document	59 Guiding Principles for Registration and Review of Class II Active Medical Devices (Draft for Comments)
Lead guideline	Negative Pressure Source Suction Device Registration and Review Guiding Principles
Total guidelines	59
Product class	Class II active medical devices
Comment deadline	Oct 8, 2026
Submission	Contact details per attached list

Key Scope

The batch covers registration and review technical standards for 59 categories of Class II active medical devices—equipment that relies on electrical energy or other power sources rather than human or gravitational force. The lead document addresses negative pressure source suction devices, with the full portfolio spanning diverse powered medical equipment categories.

Market Impact Analysis

The simultaneous release of 59 draft guidelines represents one of CMDE’s largest standardization efforts for mid-risk active devices, creating a comprehensive regulatory roadmap for manufacturers navigating China’s Class II registration pathway. For domestic and international device makers, the consolidated guidance reduces interpretive ambiguity during application preparation, potentially shortening registration timelines by clarifying technical documentation, clinical evidence, and testing requirements.

The Oct 8 comment deadline provides a five-week window for industry feedback, suggesting regulators aim to finalize the guidelines by year-end. The focus on Class II active devices—a category that includes infusion pumps, patient monitors, and therapeutic ultrasound equipment—signals intensified scrutiny of powered devices that pose moderate risk but are produced by a fragmented supplier base.

Forward-Looking Statement

Industry analysts expect the finalized 59 guidelines to take effect in early 2027, establishing the definitive regulatory baseline for Class II active device registrations through the remainder of the decade. Manufacturers with pending applications or pipeline products in the covered categories should review the drafts closely, as final versions may introduce new testing protocols or clinical data requirements not explicitly mandated under previous informal guidance. The bulk release approach suggests CMDE is moving toward systematic catalog-wide standardization rather than reactive, product-specific rulemaking, a shift that could accelerate overall review efficiency but demands proactive compliance monitoring across broad device portfolios.-China Health Reform Pulse

Policy Source: https://www.cmde.org.cn/flfg/zdyz/zqyjg/20260901134127123.html